Effects of linagliptin vs glimepiride stratified by prior insulin secretagogue use in the cardiovascular outcome study of linagliptin versus glimepiride in type 2 diabetes (CAROLINA) trial

被引：0
|
作者：
McGuire, D. K. [1 ]
Rosenstock, J. [2 ]
Johansen, O. E. [3 ]
Zinman, B. J. [4 ]
Khunti, K. [5 ]
Mattheus, M. [6 ]
Lund, S. S. [3 ]
Espeland, M. A. [7 ]
Marx, N. [8 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[2] Dallas Diabet Res Ctr Med City, Dallas, TX USA
[3] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[4] Univ Hlth Network, Lunenfeld Tanenbaum Res Inst, Mt Sinai Hosp, Toronto, ON, Canada
[5] Univ Leicester, Leicester, Leics, England
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[7] Wake Forest Univ, Winston Salem, NC 27101 USA
[8] RWTH Univ Hosp Aachen, Aachen, Germany
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3356 / 3356
页数：1
相关论文
共 50 条
  • [1] Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
    Marx, Nikolaus
    Rosenstock, Julio
    Kahn, Steven E.
    Zinman, Bernard
    Kastelein, John J.
    Lachin, John M.
    Espeland, Mark A.
    Bluhmki, Erich
    Mattheus, Michaela
    Ryckaert, Bart
    Patel, Sanjay
    Johansen, Odd Erik
    Woerle, Hans-Juergen
    DIABETES & VASCULAR DISEASE RESEARCH, 2015, 12 (03): : 164 - 174
  • [2] Baseline characteristics of participants enrolled in the cardiovascular outcome study of linagliptin versus glimepiride in early type 2 diabetes (CAROLINA)
    Marx, N.
    Rosenstock, J.
    Kahn, S. E.
    Zinman, B.
    Kastelein, J. J.
    Lachin, J.
    Espeland, M. A.
    Bluhmki, E.
    Mattheus, M.
    Patel, S.
    Johansen, O.
    Woerle, H. -J.
    DIABETOLOGIA, 2013, 56 : S36 - S37
  • [3] Baseline Characteristics of Participants Enrolled in the CARdiovascular Outcome Study of LINAgliptin versus Glimepiride in Early Type 2 Diabetes (CAROLINA)
    Marx, Nikolaus
    Rosenstock, Julio
    Kahn, Steven
    Zinman, Bernard
    Kastelein, John J.
    Lachin, John M.
    Bluhmki, Erich
    Mattheus, Michaela
    Patel, Sanjay
    Johansen, Odd Erik
    Woerle, Hans-Juergen
    DIABETES, 2013, 62 : A602 - A602
  • [4] Effects of linagliptin (LINA) versus glimepiride (GLIM) on cognitive performance in type 2 diabetes: the CAROLINA COGNITION study
    Biessels, G. J.
    Verhagen, C.
    Janssen, J.
    van den Berg, E.
    Passera, A.
    Wallenstein, G.
    Zinman, B.
    Espeland, M. E.
    Johansen, O. E.
    DIABETOLOGIA, 2019, 62 : S281 - S282
  • [5] Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
    Rosenstock, Julio
    Kahn, Steven E.
    Johansen, Odd Erik
    Zinman, Bernard
    Espeland, Mark A.
    Woerle, Hans J.
    Pfarr, Egon
    Keller, Annett
    Mattheus, Michaela
    Baanstra, David
    Meinicke, Thomas
    George, Jyothis T.
    von Eynatten, Maximilian
    McGuire, Darren K.
    Marx, Nikolaus
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (12): : 1155 - 1166
  • [6] Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial
    Rosenstock, Julio
    Kolkailah, Ahmed A.
    McGuire, Darren K.
    Espeland, Mark A.
    Mattheus, Michaela
    Pfarr, Egon
    Lund, Soren S.
    Marx, Nikolaus
    DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1453 - 1463
  • [7] Rationale and design of the CAROLINA®-cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus
    Biessels, Geert Jan
    Janssen, Jolien
    van den Berg, Esther
    Zinman, Bernard
    Espeland, Mark A.
    Mattheus, Michaela
    Johansen, Odd Erik
    BMC NEUROLOGY, 2018, 18
  • [8] Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial (vol 322, pg 1155, 2019)
    Rosenstock, J.
    Kahn, S. E.
    Johansen, O. E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (21): : 2138 - 2138
  • [9] Rationale and design of the CAROLINA® - cognition substudy: A randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus
    Biessels G.J.
    Janssen J.
    van den Berg E.
    Zinman B.
    Espeland M.A.
    Mattheus M.
    Johansen O.E.
    BMC Neurology, 18 (1)
  • [10] Linagliptin versus placebo followed by glimepiride in type 2 diabetes patients with moderate to severe renal impairment
    Groop, P. -H.
    Laakso, M.
    Rosenstock, J.
    Hehnke, U.
    Tamminen, I.
    Patel, S.
    von Eynatten, M.
    Woerle, H. -J.
    DIABETOLOGIA, 2013, 56 : S364 - S365
12345